D I G I T A L D I A G N O S T I C S
Leading epigenetic therapy company Tune Therapeutics will begin a clinical trial in Hong Kong after receiving a Certificate for Clinical Trial from the Hong Kong Department of Health .
This marks the second global approval to commence a Phase 1b clinical trial for Tune-401 , an investigational epigenetic silencing therapy designed to treat chronic hepatitis B ( CHB ).
“ We ’ re taking a fresh angle on the battle against chronic hepatitis B ,” said Derek Jantz , Chief Scientific Officer , Tune Therapeutics .
“ Current standard-of-care treatments are rarely curative due to the virus mechanism of infection . But by employing epigenetic silencing to target both integrated viral DNA and cccDNA , we are replicating the natural processes observed in spontaneous functional cure and aiming to make that outcome the norm in HBV treatment .”
The company ’ s leading therapeutic candidate , Tune-401 , has now been approved for clinical trials in both Hong Kong and New Zealand .
TUNE THERAPEUTICS RECEIVES APPROVAL TO INITIATE CLINICAL TRIAL IN HONG KONG FOR HEPB EPIGENETIC SILENCER
www . intelligenthealth . tech 63